Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E6NH
|
|||
| Former ID |
DNCL001705
|
|||
| Drug Name |
MEDI-570
|
|||
| Indication | Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 1 | [1] | |
| Company |
AstraZeneca; MedImmune
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Inducible T-cell costimulator (ICOS) | Target Info | Modulator | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Intestinal immune network for IgA production | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| WikiPathways | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01127321) A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus. U.S. National Institutes of Health. | |||
| REF 2 | B-cell targeted therapeutics in clinical development. Arthritis Res Ther. 2013;15 Suppl 1:S4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.